Fintel reports that on May 23, 2025, Leerink Partners upgraded their outlook for Fulcrum Therapeutics (NasdaqGM:FULC) from ...

Shares of Fulcrum Therapeutics (NASDAQ:FULC) rose on Friday after Leerink Partners upgraded the Cambridge, Massachusetts-based biopharma, citing a favorable risk-reward setup ahead of a trial readout ...

Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it ...

Analysts were effusive about Merus’ new HNSCC data, writing that petosemtamab could “become the standard of care” in the ...

Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a “positive readthrough” from the J&J’s (JNJ) in-licensing of an oral ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Leerink Partners analyst Mani Foroohar reiterated a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price target of $22.00. The company’s shares closed ye ...

Leerink downgraded Accolade (ACCD) to Market Perform from Outperform with a price target of $7.03, down from $9.50, after the company agreed to an acquisition by Transcarent. The firm views the ...

Leerink Partners, an advisory firm specializing in health-care deals, has hired two investment bankers from Evercore Inc. Bernhard Sakmann and Justin Reed will be joining Leerink and will be based ...

Fintel reports that on May 23, 2025, Leerink Partners upgraded their outlook for Fulcrum Therapeutics (NasdaqGM:FULC) from Market Perform to Outperform. As of May 7, 2025, the average one-year ...